» Articles » PMID: 36911232

Population-based Virucidal Phthalocyanine Gargling/rinsing Protocol to Reduce the Risk of Coronavirus Disease-2019: a Community Trial

Abstract

Aim: In this community trial, the objective was to evaluate the incidence of coronavirus disease-2019 (COVID-19) cases in two similar communities in three distinct phases: 1 (before the intervention), 2 (during the intervention), and 3 (after the intervention).

Methods: The test community received the oral antiseptic intervention (experimental), while the control community did not. The official information agency ("Statewise System for Data Analysis") provided the number of confirmed COVID-19 cases. Data were analyzed according to the three phases per epidemiological week (epi) using the R Core Team (2021) program. The relative risk and 95% confidence intervals between the cumulative incidence values of the test and control communities were calculated for each period. In the test community, a total of 995 residents over 10 years of age received two bottles containing 600 ml of mouthwash containing antiviral phthalocyanine derivative (APD). The participants were asked to gargle/rinse with of 5 mL of the mouthwash containing ADP 3 to 5 times a day, for 1 min, until the bottles were empty.

Results: In phases 1 and 3, the disease risk between the two communities did not differ significantly (p>0.05), while in phase 2, the disease risk was 54% lower in the test community than in the control community.

Conclusion: The use of the APD mouthwash protocol seems to reduce the COVID-19 incidence at the population level, and further studies are needed to confirm its protective effect under more precisely controlled conditions.

Citing Articles

Can toothbrushing reduce the intraoral viral load of SARS-CoV-2? A pilot study with a dentifrice containing an antimicrobial phthalocyanine derivative.

Poleti M, Gregorio D, Bistaffa A, Vilhena F, Simao A, Mori M GMS Hyg Infect Control. 2024; 19:Doc32.

PMID: 38993377 PMC: 11238404. DOI: 10.3205/dgkh000487.


Risk of SARS-CoV-2 infection in dental healthcare workers - a systematic review and meta-analysis.

Schwarz K, Nienhaus A, Diel R GMS Hyg Infect Control. 2024; 19:Doc09.

PMID: 38655123 PMC: 11035909. DOI: 10.3205/dgkh000464.


Preprocedural Viral Load Effects of Oral Antiseptics on SARS-CoV-2 in Patients with COVID-19: A Systematic Review.

Ting M, Dahlkemper A, Schwartz J, Woodfork M, Suzuki J Biomedicines. 2023; 11(6).

PMID: 37371789 PMC: 10295900. DOI: 10.3390/biomedicines11061694.

References
1.
Fernandes Matuck B, Dolhnikoff M, Duarte-Neto A, Maia G, Gomes S, Sendyk D . Salivary glands are a target for SARS-CoV-2: a source for saliva contamination. J Pathol. 2021; 254(3):239-243. PMC: 8250228. DOI: 10.1002/path.5679. View

2.
Orcina B, Vilhena F, Oliveira R, Marques da Costa Alves L, Araki K, Toma S . A Phthalocyanine Derivate Mouthwash to Gargling/Rinsing as an Option to Reduce Clinical Symptoms of COVID-19: Case Series. Clin Cosmet Investig Dent. 2021; 13:47-50. PMC: 7899311. DOI: 10.2147/CCIDE.S295423. View

3.
Fernandes Matuck B, Dolhnikoff M, Maia G, Sendyk D, Zarpellon A, Gomes S . Periodontal tissues are targets for Sars-Cov-2: a post-mortem study. J Oral Microbiol. 2021; 13(1):1848135. PMC: 7717160. DOI: 10.1080/20002297.2020.1848135. View

4.
Carrouel F, Valette M, Gadea E, Esparcieux A, Illes G, Langlois M . Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial. Clin Microbiol Infect. 2021; 27(10):1494-1501. PMC: 8142805. DOI: 10.1016/j.cmi.2021.05.028. View

5.
Carrouel F, Goncalves L, Conte M, Campus G, Fisher J, Fraticelli L . Antiviral Activity of Reagents in Mouth Rinses against SARS-CoV-2. J Dent Res. 2020; 100(2):124-132. PMC: 7582358. DOI: 10.1177/0022034520967933. View